Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice

The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Borghetti, Alberto, Giacomelli, Andrea, Borghi, Vanni, Ciccullo, Arturo, Dusina, Alex, Fabbiani, Massimiliano, Rusconi, Stefano, Zazzi, Maurizio, Mussini, Cristina, Di Giambenedetto, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314943/
https://www.ncbi.nlm.nih.gov/pubmed/34327247
http://dx.doi.org/10.1093/ofid/ofab103
_version_ 1783729639835828224
author Borghetti, Alberto
Giacomelli, Andrea
Borghi, Vanni
Ciccullo, Arturo
Dusina, Alex
Fabbiani, Massimiliano
Rusconi, Stefano
Zazzi, Maurizio
Mussini, Cristina
Di Giambenedetto, Simona
author_facet Borghetti, Alberto
Giacomelli, Andrea
Borghi, Vanni
Ciccullo, Arturo
Dusina, Alex
Fabbiani, Massimiliano
Rusconi, Stefano
Zazzi, Maurizio
Mussini, Cristina
Di Giambenedetto, Simona
author_sort Borghetti, Alberto
collection PubMed
description The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.
format Online
Article
Text
id pubmed-8314943
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83149432021-07-28 Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice Borghetti, Alberto Giacomelli, Andrea Borghi, Vanni Ciccullo, Arturo Dusina, Alex Fabbiani, Massimiliano Rusconi, Stefano Zazzi, Maurizio Mussini, Cristina Di Giambenedetto, Simona Open Forum Infect Dis Brief Report The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF. Oxford University Press 2021-03-06 /pmc/articles/PMC8314943/ /pubmed/34327247 http://dx.doi.org/10.1093/ofid/ofab103 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Borghetti, Alberto
Giacomelli, Andrea
Borghi, Vanni
Ciccullo, Arturo
Dusina, Alex
Fabbiani, Massimiliano
Rusconi, Stefano
Zazzi, Maurizio
Mussini, Cristina
Di Giambenedetto, Simona
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
title Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
title_full Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
title_fullStr Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
title_full_unstemmed Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
title_short Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
title_sort nucleoside reverse-transcriptase inhibitor resistance mutations predict virological failure in human immunodeficiency virus-positive patients during lamivudine plus dolutegravir maintenance therapy in clinical practice
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314943/
https://www.ncbi.nlm.nih.gov/pubmed/34327247
http://dx.doi.org/10.1093/ofid/ofab103
work_keys_str_mv AT borghettialberto nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT giacomelliandrea nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT borghivanni nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT cicculloarturo nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT dusinaalex nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT fabbianimassimiliano nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT rusconistefano nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT zazzimaurizio nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT mussinicristina nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice
AT digiambenedettosimona nucleosidereversetranscriptaseinhibitorresistancemutationspredictvirologicalfailureinhumanimmunodeficiencyviruspositivepatientsduringlamivudineplusdolutegravirmaintenancetherapyinclinicalpractice

Ejemplares similares